Compare · RELX vs RFL
RELX vs RFL
Side-by-side comparison of RELX PLC PLC (RELX) and Rafael Holdings Inc. (RFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- RELX operates in Real Estate, while RFL operates in Finance - the two are in different parts of the market.
- RELX is the larger of the two at $65.44B, about 561.9x RFL ($116.5M).
- RELX has been more active in the news (2 items in the past 4 weeks vs 1 for RFL).
- RELX has more recent analyst coverage (12 ratings vs 0 for RFL).
- Company
- RELX PLC PLC
- Rafael Holdings Inc.
- Price
- $35.88-1.41%
- $2.25+4.16%
- Market cap
- $65.44B
- $116.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Real Estate
- Real Estate
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- 2018
- News (4w)
- 2
- 1
- Recent ratings
- 12
- 0
RELX PLC PLC
RELX PLC provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Scientific, Technical & Medical; Risk; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics that help institutions and professionals to progress in science and advance healthcare. The Risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. The Legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as enhance the productivity. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier PLC and changed its name to RELX PLC in July 2015. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.
Rafael Holdings Inc.
Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Latest RELX
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
- 2026 LexisNexis U.S. Home Insurance Trends Report: Claims Severity Reaches All-Time High While Frequency Declines
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
- SEC Form 6-K filed by RELX PLC PLC
Latest RFL
- Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
- Exec Chairman, CEO & President Jonas Howard S was granted 54,945 units of Class B Common Stock, increasing direct ownership by 12% to 512,030 units (SEC Form 4)
- Rafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Financial Officer Polinsky David covered exercise/tax liability with 2,386 units of Class B Common Stock, decreasing direct ownership by 0.79% to 299,111 units (SEC Form 4)
- Exec Chairman, CEO & President Jonas Howard S was granted 142,857 units of Class B Common Stock and covered exercise/tax liability with 8,786 units of Class B Common Stock, increasing direct ownership by 42% to 457,085 units (SEC Form 4)
- SEC Form 10-Q filed by Rafael Holdings Inc.
- Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
- Rafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C